{"id":7,"date":"2015-12-04T02:08:28","date_gmt":"2015-12-04T02:08:28","guid":{"rendered":"http:\/\/theme-fusion.com\/avada\/construction\/?page_id=7"},"modified":"2019-09-03T15:26:58","modified_gmt":"2019-09-03T13:26:58","slug":"novigenix","status":"publish","type":"page","link":"https:\/\/colox.ch\/fr\/novigenix\/","title":{"rendered":"Novigenix"},"content":{"rendered":"

<\/div>
<\/div>
<\/div>
<\/div>

Novigenix, une entreprise innovante<\/span><\/h1>\n<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div>
<\/div>
<\/div>

Innovation en biopsie liquide pour \u00e9radiquer le cancer<\/h1>\n<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>
<\/span><\/div><\/div><\/div>
<\/div><\/div><\/div>

Novigenix est une entreprise de diagnostic m\u00e9dical qui innove dans le domaine de la biopsie liquide pour la d\u00e9tection pr\u00e9coce du cancer et la m\u00e9decine de pr\u00e9cision.<\/p>\n

Novigenix a d\u00e9veolopp\u00e9 une plateforme technologique propri\u00e9taire nomm\u00e9e LITOseek™ qui combine l’analyse transcriptomique des cellules immunitaires dans le sang avec la mesure de marqueurs de la tumeur dans des algorithmes pr\u00e9dictifs.
\n 
\nLa premi\u00e8re g\u00e9n\u00e9ration du test sanguin Colox\u00ae bas\u00e9 sur l’analyse transcriptomique des cellules immunitaires et valid\u00e9 cliniquement a \u00e9t\u00e9 d\u00e9velopp\u00e9 dans le but de r\u00e9duire le taux de mortalit\u00e9 du cancer du c\u00f4lon gr\u00e2ce \u00e0 une d\u00e9tection et une prise en charge pr\u00e9coces de la maladie.<\/p>\n

Novigenix poursuit le d\u00e9veloppement de sa plateforme technologique LITOseek en \u00e9tandant son domaine d’application \u00e0 la m\u00e9decine de pr\u00e9cision.<\/p>\n<\/div>

<\/div>
<\/div>
<\/div>
En savoir plus sur Novigenix<\/span><\/a><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/div>
<\/div>
<\/div>
<\/div>

Conseillers scientifiques<\/span><\/h1>\n<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div><\/div><\/div>

Dr. Marianne Murphy<\/strong><\/h3>\n

Immunologist with international recognition in the fields of T cell and cytokine biology, and with 25 years of industry experience in various leading positions at NatiMab Therapeutics, RiboVax Biotechnologies, and Celltech R&D.<\/p>\n

<\/h3>\n

Dr. Reinhard Ebner<\/strong><\/h3>\n

Senior research manager and investigator specialized in solving complex questions in molecular and cell biology, particularly as they relate to disease mechanism and drug discovery. More than 30 years of experience in US academia and industrie (Stanford, Genentech, NIH, Cytotest).<\/p>\n

<\/h3>\n

Prof. Stephan Morgenthaler<\/strong><\/h3>\n

Full Professor at Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne (EPFL), Chair of Applied Statistics, Lausanne, Switzerland<\/p>\n

<\/h3>\n

Dr. Antoine de Weck<\/strong><\/h3>\n

Investigator at Novartis Institute for Biomedical Research and specialist in Computational Biology, Basel, Switzerland<\/p>\n<\/div>

<\/div><\/div><\/div>

Prof. Christoph Beglinger, MD<\/strong><\/h3>\n

Specialist in Gastroenterology, formerly Head of the Department of Biomedicine at the University Hospital of Basel, currently Head of Clinical Research at St. Claraspital in Basel, Switzerland<\/p>\n

<\/h3>\n

Prof. Gian Dorta, MD<\/strong><\/h3>\n

Specialist in Gastroenterology, Department of Internal Medicine, Section Gastroenterology and Hepatology, Academic Medical Center, Lausanne (CHUV), Switzerland<\/p>\n

<\/h3>\n

Dr. Cristina Nichita, MD<\/strong><\/h3>\n

Specialist in Gastroenterology, Centre M\u00e9dical d\u2019Epalinge, VIDY MED Group, Epalinges, Switzerland<\/p>\n

<\/h3>\n

Prof. Peter Bauerfeind, MD<\/strong><\/h3>\n

Specialist in Gastroenterology, Clinic for Gastroenterology and Hepatology, University Hospital, Zurich (USZ), Switzerland<\/p>\n

<\/h3>\n

Dr. Philippe Maerten, MD PhD<\/strong><\/h3>\n

Specialist in Gastroenterology, Hirslanden Clinic Cecil, Lausanne, Switzerland<\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":1795,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-7","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nNovigenix - Colox<\/title>\n<meta name=\"description\" content=\"Le cancer du c\u00f4lon tue chaque ann\u00e9e 1'600 personnes en Suisse. Alors qu\u2019une d\u00e9tection pr\u00e9coce augmente les chances de survie de 90%\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/colox.ch\/fr\/novigenix\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novigenix\" \/>\n<meta property=\"og:description\" content=\"Start-up du secteur biotech, nous sommes par essence un agent de changement et donc d\u00e9termin\u00e9 \u00e0 faire bouger les lignes. Le cancer du c\u00f4lon tue chaque ann\u00e9e 1'600 personnes en Suisse. Alors qu\u2019une d\u00e9tection pr\u00e9coce augmente les chances de survie de 90%, seulement 30% de la population suisse se fait d\u00e9pister. Cette r\u00e9alit\u00e9 est\u00a0insens\u00e9e.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/colox.ch\/fr\/novigenix\/\" \/>\n<meta property=\"og:site_name\" content=\"Colox\" \/>\n<meta property=\"article:modified_time\" content=\"2019-09-03T13:26:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Novigenix\" \/>\n<meta name=\"twitter:description\" content=\"Start-up du secteur biotech, nous sommes par essence un agent de changement et donc d\u00e9termin\u00e9 \u00e0 faire bouger les lignes. Le cancer du c\u00f4lon tue chaque ann\u00e9e 1'600 personnes en Suisse. Alors qu\u2019une d\u00e9tection pr\u00e9coce augmente les chances de survie de 90%, seulement 30% de la population suisse se fait d\u00e9pister. Cette r\u00e9alit\u00e9 est\u00a0insens\u00e9e.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-twitter-home-site-novigenix-1024px.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/colox.ch\/fr\/novigenix\/\",\"url\":\"https:\/\/colox.ch\/fr\/novigenix\/\",\"name\":\"Novigenix - Colox\",\"isPartOf\":{\"@id\":\"https:\/\/colox.ch\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/colox.ch\/fr\/novigenix\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/colox.ch\/fr\/novigenix\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-1200px.jpg\",\"datePublished\":\"2015-12-04T02:08:28+00:00\",\"dateModified\":\"2019-09-03T13:26:58+00:00\",\"description\":\"Le cancer du c\u00f4lon tue chaque ann\u00e9e 1'600 personnes en Suisse. Alors qu\u2019une d\u00e9tection pr\u00e9coce augmente les chances de survie de 90%\",\"breadcrumb\":{\"@id\":\"https:\/\/colox.ch\/fr\/novigenix\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/colox.ch\/fr\/novigenix\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/colox.ch\/fr\/novigenix\/#primaryimage\",\"url\":\"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-1200px.jpg\",\"contentUrl\":\"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-1200px.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Novigenix\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/colox.ch\/fr\/novigenix\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/colox.ch\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novigenix\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/colox.ch\/de\/#website\",\"url\":\"https:\/\/colox.ch\/de\/\",\"name\":\"Colox\",\"description\":\"The new generation blood test\",\"publisher\":{\"@id\":\"https:\/\/colox.ch\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/colox.ch\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/colox.ch\/de\/#organization\",\"name\":\"Novigenix SA\",\"url\":\"https:\/\/colox.ch\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"contentUrl\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"width\":700,\"height\":297,\"caption\":\"Novigenix SA\"},\"image\":{\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novigenix - Colox","description":"Le cancer du c\u00f4lon tue chaque ann\u00e9e 1'600 personnes en Suisse. Alors qu\u2019une d\u00e9tection pr\u00e9coce augmente les chances de survie de 90%","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/colox.ch\/fr\/novigenix\/","og_locale":"fr_FR","og_type":"article","og_title":"Novigenix","og_description":"Start-up du secteur biotech, nous sommes par essence un agent de changement et donc d\u00e9termin\u00e9 \u00e0 faire bouger les lignes. Le cancer du c\u00f4lon tue chaque ann\u00e9e 1'600 personnes en Suisse. Alors qu\u2019une d\u00e9tection pr\u00e9coce augmente les chances de survie de 90%, seulement 30% de la population suisse se fait d\u00e9pister. Cette r\u00e9alit\u00e9 est\u00a0insens\u00e9e.","og_url":"https:\/\/colox.ch\/fr\/novigenix\/","og_site_name":"Colox","article_modified_time":"2019-09-03T13:26:58+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-1200px.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_title":"Novigenix","twitter_description":"Start-up du secteur biotech, nous sommes par essence un agent de changement et donc d\u00e9termin\u00e9 \u00e0 faire bouger les lignes. Le cancer du c\u00f4lon tue chaque ann\u00e9e 1'600 personnes en Suisse. Alors qu\u2019une d\u00e9tection pr\u00e9coce augmente les chances de survie de 90%, seulement 30% de la population suisse se fait d\u00e9pister. Cette r\u00e9alit\u00e9 est\u00a0insens\u00e9e.","twitter_image":"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-twitter-home-site-novigenix-1024px.jpg","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/colox.ch\/fr\/novigenix\/","url":"https:\/\/colox.ch\/fr\/novigenix\/","name":"Novigenix - Colox","isPartOf":{"@id":"https:\/\/colox.ch\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/colox.ch\/fr\/novigenix\/#primaryimage"},"image":{"@id":"https:\/\/colox.ch\/fr\/novigenix\/#primaryimage"},"thumbnailUrl":"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-1200px.jpg","datePublished":"2015-12-04T02:08:28+00:00","dateModified":"2019-09-03T13:26:58+00:00","description":"Le cancer du c\u00f4lon tue chaque ann\u00e9e 1'600 personnes en Suisse. Alors qu\u2019une d\u00e9tection pr\u00e9coce augmente les chances de survie de 90%","breadcrumb":{"@id":"https:\/\/colox.ch\/fr\/novigenix\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/colox.ch\/fr\/novigenix\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/colox.ch\/fr\/novigenix\/#primaryimage","url":"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-1200px.jpg","contentUrl":"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-1200px.jpg","width":1200,"height":630,"caption":"Novigenix"},{"@type":"BreadcrumbList","@id":"https:\/\/colox.ch\/fr\/novigenix\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/colox.ch\/"},{"@type":"ListItem","position":2,"name":"Novigenix"}]},{"@type":"WebSite","@id":"https:\/\/colox.ch\/de\/#website","url":"https:\/\/colox.ch\/de\/","name":"Colox","description":"The new generation blood test","publisher":{"@id":"https:\/\/colox.ch\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/colox.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/colox.ch\/de\/#organization","name":"Novigenix SA","url":"https:\/\/colox.ch\/de\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/","url":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","contentUrl":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","width":700,"height":297,"caption":"Novigenix SA"},"image":{"@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/pages\/7"}],"collection":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/comments?post=7"}],"version-history":[{"count":0,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/pages\/7\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/media\/1795"}],"wp:attachment":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/media?parent=7"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}